AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US
On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States.
The UriFind® bladder cancer assay clinical trial in the United States, involving more than 1,000 patients across multiple centers, has officially begun patient enrollment, according to AnchorDx. In this perspective registrational study, the effectiveness of a non-invasive, quantitative real-time PCR (qPCR) assay developed to identify two DNA methylation biomarkers in urine samples from patients suspected of having...
